Asia Pacific Influenza Treatment 麻豆原创 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM0820028

Publication Date:

August 26, 2020

Pages:

Publisher:

Grace 麻豆原创 Data

Countries:

Asia Pacific [1]

USD 3,000.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Asia Pacific influenza treatment market will grow by 6.8% annually with a total addressable market cap of $2,873.1 million over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic.
Highlighted with 30 tables and 43 figures, this 96-page report 鈥淎sia Pacific Influenza Treatment 麻豆原创 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country.

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Oseltamivir Phosphate
鈥� Baloxavir Marboxil
鈥� Peramivir
鈥� Zanamivir
鈥� Other Drugs

Based on Influenza Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Influenza A
鈥� Influenza B
鈥� Influenza C

Based on Administration Route, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Oral Administration
鈥� Other Administration Routes

Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Retail Pharmacy
鈥� Hospital Pharmacy
鈥� Clinics
鈥� Online Stores

Geographically, the following national/local markets are fully investigated:
鈥� Japan
鈥� China
鈥� South Korea
鈥� Australia
鈥� India
鈥� Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific influenza treatment market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 5
1.1 Industry Definition and Research Scope 5
1.1.1 Industry Definition 5
1.1.2 Research Scope 6
1.2 Research Methodology 9
1.2.1 Overview of 麻豆原创 Research Methodology 9
1.2.2 麻豆原创 Assumption 10
1.2.3 Secondary Data 10
1.2.4 Primary Data 10
1.2.5 Data Filtration and Model Design 12
1.2.6 麻豆原创 Size/Share Estimation 13
1.2.7 Research Limitations 14
1.3 Executive Summary 15
2 麻豆原创 Overview and Dynamics 17
2.1 麻豆原创 Size and Forecast 17
2.1.1 Impact of COVID-19 on the 麻豆原创 18
2.2 Major Growth Drivers 20
2.3 麻豆原创 Restraints and Challenges 24
2.4 Emerging Opportunities and 麻豆原创 Trends 27
2.5 Porter鈥檚 Fiver Forces Analysis 31
3 Segmentation of Asia Pacific 麻豆原创 by Product Type 35
3.1 麻豆原创 Overview by Product Type 35
3.2 Oseltamivir Phosphate 37
3.3 Baloxavir Marboxil 38
3.4 Peramivir 39
3.5 Zanamivir 40
3.6 Other Drugs 41
4 Segmentation of Asia Pacific 麻豆原创 by Influenza Type 42
4.1 麻豆原创 Overview by Influenza Type 42
4.2 Influenza A 44
4.3 Influenza B 45
4.4 Influenza C 46
5 Segmentation of Asia Pacific 麻豆原创 by Administration Route 47
5.1 麻豆原创 Overview by Administration Route 47
5.2 Oral Administration 49
5.3 Other Administration Routes 50
6 Segmentation of Asia Pacific 麻豆原创 by Distribution Channel 51
6.1 麻豆原创 Overview by Distribution Channel 51
6.2 Retail Pharmacy 53
6.3 Hospital Pharmacy 54
6.4 Clinics 55
6.5 Online Stores 56
7 Asia-Pacific 麻豆原创 2019-2030 by Country 57
7.1 Overview of Asia-Pacific 麻豆原创 57
7.2 Japan 60
7.3 China 63
7.4 Australia 65
7.5 India 67
7.6 South Korea 69
7.7 Rest of APAC Region 71
8 Competitive Landscape 73
8.1 Overview of Key Vendors 73
8.2 New Product Launch, Partnership, Investment, and M&A 76
8.3 Company Profiles 77
AstraZeneca Plc 77
BioCryst Pharmaceuticals Inc. 79
Biondvax 80
Daiichi Sankyo Company 81
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) 82
GlaxoSmithKline Plc 83
Mylan N.V 84
Natco Pharma Limited 85
Novartis AG 86
Sanofi 87
Seqirus 88
Teva Pharmaceutical Industries Limited 89
9 Investing in Asia Pacific 麻豆原创: Risk Assessment and Management 90
9.1 Risk Evaluation of Asia Pacific 麻豆原创 90
9.2 Critical Success Factors (CSFs) 93
Related Reports and Products 96

Companies Mentioned:

Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.